{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:06:10Z","timestamp":1770285970621,"version":"3.49.0"},"reference-count":99,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,15]]},"abstract":"<jats:p>Therapy for patients with chronic lymphocytic leukemia (CLL) has greatly changed over the past few years. After years of stagnation, with treatment revolving around the use of rather ineffective drugs such as alkylators, many patients are now being treated with more effective agents such as purine analogs either alone or combined with other drugs and\/or monoclonal antibodies. Treatment of patients refractory to these treatments is particularly challenging and should be decided only upon a careful evaluation of the disease, patient characteristics, and prognostic factors. Refractory disease should be clearly separated from relapsing disease. The only curative therapy for patients with CLL, including those with refractory disease, is allogeneic stem cell transplantation. However, the use of allogeneic transplantation is limited because of the advanced age of most patients and the high transplant-related mortality (TRM). Transplants with nonmyeloablative regimens may reduce TRM and allow more patients to receive transplants more safely. For patients in whom an allogeneic transplantation is not feasible or in whom it is deemed inappropriate, participation in phase 2 trials should be encouraged. Finally, to investigate mechanisms to overcome resistance to therapy in CLL and to identify patients that might gain benefit from early, intensive therapies (eg, based on biologic markers) constitute a challenge that needs active investigation.<\/jats:p>","DOI":"10.1182\/blood-2005-02-0819","type":"journal-article","created":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T03:08:10Z","timestamp":1128481690000},"page":"1276-1283","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":73,"title":["How I treat refractory CLL"],"prefix":"10.1182","volume":"107","author":[{"given":"Emili","family":"Montserrat","sequence":"first","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gine\u0301","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Oncology, Department of Hematology, Institut d'Investigacions Biome\u0300diques August Pi i Sunyer, Hospital Cli\u0301nic, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111823493236300_REF1","unstructured":"Mu\u0308ller-Hermelink HK, Catovsky D, Montserrat E, Harris NL. Chronic lymphocytic leukaemia\/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumors: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 127-130."},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333: 1052-1057.","DOI":"10.1056\/NEJM199510193331606"},{"key":"2019111823493236300_REF3","doi-asserted-by":"crossref","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352: 804-815.","DOI":"10.1056\/NEJMra041720"},{"key":"2019111823493236300_REF4","unstructured":"Ries L, Eismer MP, Kosary CL. National Cancer Institute, Bethesda MD, 2000. 1993."},{"key":"2019111823493236300_REF5","doi-asserted-by":"crossref","unstructured":"Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. In: Hematology 2004: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2004: 163-183.","DOI":"10.1182\/asheducation-2004.1.163"},{"key":"2019111823493236300_REF6","doi-asserted-by":"crossref","unstructured":"Montserrat E. Current and developing chemotherapy for CLL. Med Oncol. 2002;19: S11-S19.","DOI":"10.1385\/MO:19:2S:S11"},{"key":"2019111823493236300_REF7","doi-asserted-by":"crossref","unstructured":"Montserrat E. CLL therapy: progress at last! Blood. 2005;105: 2-3.","DOI":"10.1182\/blood-2004-10-3855"},{"key":"2019111823493236300_REF8","doi-asserted-by":"crossref","unstructured":"Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med. 1989;110: 236-238.","DOI":"10.7326\/0003-4819-110-3-236"},{"key":"2019111823493236300_REF9","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87: 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2019111823493236300_REF10","doi-asserted-by":"crossref","unstructured":"Oscier D, Fegan C, Hillmen P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125: 294-317.","DOI":"10.1111\/j.1365-2141.2004.04898.x"},{"key":"2019111823493236300_","unstructured":"Hallek M, Bergmann M, Emmerich B. Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment. Onkologie. 2004;27: 97-104."},{"key":"2019111823493236300_REF12","doi-asserted-by":"crossref","unstructured":"Hallek M, Stahel RA, Greil R. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. Ann Oncol. 2005;16(suppl 1): i50-i51.","DOI":"10.1093\/annonc\/mdi806"},{"key":"2019111823493236300_REF13","doi-asserted-by":"crossref","unstructured":"Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43: 1755-1762.","DOI":"10.1080\/1042819021000006547"},{"key":"2019111823493236300_REF14","doi-asserted-by":"crossref","unstructured":"Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21: 1278-1284.","DOI":"10.1200\/JCO.2003.08.100"},{"key":"2019111823493236300_REF15","doi-asserted-by":"crossref","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103: 3278-3281.","DOI":"10.1182\/blood-2003-10-3729"},{"key":"2019111823493236300_REF16","doi-asserted-by":"crossref","unstructured":"Montserrat E, Lopez-Lorenzo JL, Manso F, et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma. 1996;21: 467-472.","DOI":"10.3109\/10428199609093445"},{"key":"2019111823493236300_REF17","doi-asserted-by":"crossref","unstructured":"Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94: 2033-2039.","DOI":"10.1002\/cncr.0680"},{"key":"2019111823493236300_REF18","doi-asserted-by":"crossref","unstructured":"Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100: 1177-1184.","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"2019111823493236300_REF19","doi-asserted-by":"crossref","unstructured":"Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100: 1404-1409.","DOI":"10.1182\/blood-2001-11-0066"},{"key":"2019111823493236300_REF20","doi-asserted-by":"crossref","unstructured":"Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85: 1580-1589.","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol. 2003;121: 692-702.","DOI":"10.1046\/j.1365-2141.2003.04336.x"},{"key":"2019111823493236300_","unstructured":"Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 2003;63: 36-38."},{"key":"2019111823493236300_REF23","doi-asserted-by":"crossref","unstructured":"Lucas DM, Dewald GW, Neuberg DS, et al. Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia (CLL) patients with p53 mutations or del(17p) enrolled on a prospective phase III clinical trial: short progression free survival, irrespective of fludarabine-based treatment used [abstract]. Blood. 2004; 104: 272a. Abstract 949.","DOI":"10.1182\/blood.V104.11.949.949"},{"key":"2019111823493236300_REF24","doi-asserted-by":"crossref","unstructured":"Catovsky D, Richards S, Matutes E. Response to therapy and survival in CLL is influenced by genetic markers: preliminary analysis from the LRF CLL4 Trial [abstract]. Blood. 2004;104: 8a. Abstract 13.","DOI":"10.1182\/blood.V104.11.13.13"},{"key":"2019111823493236300_REF25","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347: 452-453.","DOI":"10.1056\/NEJM200208083470619"},{"key":"2019111823493236300_REF26","doi-asserted-by":"crossref","unstructured":"Byrd JC, Gribben JG, Peterson B, et al. Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): preliminary justification for risk-adapted therapy [abstract 476]. Blood. 2004;104: 139.","DOI":"10.1182\/blood.V104.11.476.476"},{"key":"2019111823493236300_REF27","doi-asserted-by":"crossref","unstructured":"Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood. 2004;103: 291-300.","DOI":"10.1182\/blood-2003-04-1161"},{"key":"2019111823493236300_REF28","doi-asserted-by":"crossref","unstructured":"Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91: 3379-3389.","DOI":"10.1182\/blood.V91.9.3379"},{"key":"2019111823493236300_REF29","doi-asserted-by":"crossref","unstructured":"Morales AA, Olsson A, Celsing F, et al. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer. 2005;113: 730-737.","DOI":"10.1002\/ijc.20614"},{"key":"2019111823493236300_REF30","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 2004;104: 1428-1434.","DOI":"10.1182\/blood-2003-09-3236"},{"key":"2019111823493236300_REF31","unstructured":"Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukaemia. Am J Pathol. 1928;4: 285-292."},{"key":"2019111823493236300_REF32","doi-asserted-by":"crossref","unstructured":"Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993;11: 1985-1989.","DOI":"10.1200\/JCO.1993.11.10.1985"},{"key":"2019111823493236300_REF33","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005;103: 216-228.","DOI":"10.1002\/cncr.20773"},{"key":"2019111823493236300_REF34","doi-asserted-by":"crossref","unstructured":"Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia: the possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res. 2005; 29: 389-395.","DOI":"10.1016\/j.leukres.2004.09.008"},{"key":"2019111823493236300_REF35","doi-asserted-by":"crossref","unstructured":"Partyka S, O'Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation. Leuk Lymphoma. 1999; 36: 151-155.","DOI":"10.3109\/10428199909145959"},{"key":"2019111823493236300_REF36","doi-asserted-by":"crossref","unstructured":"Cobo F, Rosinol L, Martinez A, et al. Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. Br J Haematol. 2002;119: 484-487.","DOI":"10.1046\/j.1365-2141.2002.03788.x"},{"key":"2019111823493236300_REF37","unstructured":"Tsimberidou A, O'Brien S, Khouri I, et al. Outcome in patients with Richter\u2032s syndrome treated with chemotherapy and\/or immunotherapy with or without stem cell transplantation [abstract 43]. Ann Oncol. 2005;16: v44."},{"key":"2019111823493236300_REF38","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100: 2289-2290.","DOI":"10.1182\/blood-2002-03-0892"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100: 635-639.","DOI":"10.1182\/blood.V100.2.635"},{"key":"2019111823493236300_REF40","doi-asserted-by":"crossref","unstructured":"Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5-B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004;103: 2337-2342.","DOI":"10.1182\/blood-2003-09-3277"},{"key":"2019111823493236300_REF41","doi-asserted-by":"crossref","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1750-1757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"2019111823493236300_REF42","doi-asserted-by":"crossref","unstructured":"Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol. 1997;15: 458-465.","DOI":"10.1200\/JCO.1997.15.2.458"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine in patients with advanced and\/or resistant B-chronic lymphocytic leukemia. Eur J Haematol. 1993;51: 93-97.","DOI":"10.1111\/j.1600-0609.1993.tb01599.x"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Gjedde SB, Hansen MM. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk Lymphoma. 1996;21: 317-320.","DOI":"10.3109\/10428199209067613"},{"key":"2019111823493236300_REF45","doi-asserted-by":"crossref","unstructured":"Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma. 1995;18: 493-496.","DOI":"10.3109\/10428199509059650"},{"key":"2019111823493236300_REF46","doi-asserted-by":"crossref","unstructured":"Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003;82: 759-765.","DOI":"10.1007\/s00277-003-0710-5"},{"key":"2019111823493236300_REF47","doi-asserted-by":"crossref","unstructured":"Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15: 1567-1574.","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"2019111823493236300_REF48","unstructured":"Kennedy B, Rawstron A, Haynes A. Eradication of detectable minimal residual disease with Campath-1H therapy results in prolonged survival in patients with refractory B-cell [abstract 1544]. Blood. 2001;98: 367."},{"key":"2019111823493236300_REF49","doi-asserted-by":"crossref","unstructured":"Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20: 3891-3897.","DOI":"10.1200\/JCO.2002.06.119"},{"key":"2019111823493236300_REF50","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99: 3554-3561.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2019111823493236300_REF51","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Winkler D, Kro\u0308ber A, et al. Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG) [abstract]. Blood. 2004;104: 478a. Abstract 478.","DOI":"10.1182\/blood.V104.11.478.478"},{"key":"2019111823493236300_REF52","unstructured":"Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica. 2005;90: 410-412."},{"key":"2019111823493236300_REF53","doi-asserted-by":"crossref","unstructured":"Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23: 2971-2979.","DOI":"10.1200\/JCO.2005.04.021"},{"key":"2019111823493236300_REF54","doi-asserted-by":"crossref","unstructured":"Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99: 2245-2247.","DOI":"10.1182\/blood.V99.6.2245"},{"key":"2019111823493236300_REF55","doi-asserted-by":"crossref","unstructured":"Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45: 2269-2273.","DOI":"10.1080\/10428190412331286096"},{"key":"2019111823493236300_REF56","doi-asserted-by":"crossref","unstructured":"Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101: 3413-3415.","DOI":"10.1182\/blood-2002-07-1952"},{"key":"2019111823493236300_REF57","doi-asserted-by":"crossref","unstructured":"Wierda W, Faderl S, O'Brien S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL [abstract]. Blood. 2004;104: 101a. Abstract 340.","DOI":"10.1182\/blood.V104.11.340.340"},{"key":"2019111823493236300_REF58","unstructured":"Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica. 2005;90: 1435-1436."},{"key":"2019111823493236300_REF59","doi-asserted-by":"crossref","unstructured":"Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol. 1997;96: 617-619.","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"2019111823493236300_REF60","doi-asserted-by":"crossref","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100: 768-773.","DOI":"10.1182\/blood-2002-01-0159"},{"key":"2019111823493236300_REF61","doi-asserted-by":"crossref","unstructured":"O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 1414-1420.","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"2019111823493236300_REF62","doi-asserted-by":"crossref","unstructured":"Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001; 114: 342-348.","DOI":"10.1046\/j.1365-2141.2001.02959.x"},{"key":"2019111823493236300_REF63","doi-asserted-by":"crossref","unstructured":"Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119: 976-984.","DOI":"10.1046\/j.1365-2141.2002.03959.x"},{"key":"2019111823493236300_REF64","unstructured":"Mauro FR, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002;87: 926-933."},{"key":"2019111823493236300_REF65","doi-asserted-by":"crossref","unstructured":"Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100: 3115-3120.","DOI":"10.1182\/blood-2002-03-0972"},{"key":"2019111823493236300_REF66","doi-asserted-by":"crossref","unstructured":"Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23: 4070-4078.","DOI":"10.1200\/JCO.2005.12.516"},{"key":"2019111823493236300_REF67","doi-asserted-by":"crossref","unstructured":"Rai KR, Moore JO, Boyd TE, et al. Phase 3 randomized trial of fludarabine\/cyclophosphamide chemotherapy with or without Oblimersen Sodium (Bcl-2 antisense: Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2004; 104: 100a. Abstract 338.","DOI":"10.1182\/blood.V104.11.338.338"},{"key":"2019111823493236300_REF68","doi-asserted-by":"crossref","unstructured":"Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). [abstract]. Blood. 2004;104: 101a. Abstract 341.","DOI":"10.1182\/blood.V104.11.341.341"},{"key":"2019111823493236300_REF69","doi-asserted-by":"crossref","unstructured":"Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine\/Mitoxantrone\/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma. 2004;45: 2445-2449.","DOI":"10.1080\/10428190400004521"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone: a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I\/II study. Leuk Lymphoma. 2004;45: 911-913.","DOI":"10.1080\/1042819031000123546"},{"key":"2019111823493236300_","unstructured":"Frankel AE, Fleming DR, Hall PD, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003;9: 3555-3561."},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105: 959-967.","DOI":"10.1182\/blood-2004-05-1693"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Faderl S, Rai KR, Gribben J, et al. Phase 2 study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL [abstract]. Blood. 2004;104: 293b. Abstract 4841.","DOI":"10.1182\/blood.V104.11.4841.4841"},{"key":"2019111823493236300_","unstructured":"Chanan-Khan A, Chanan-Khan AA, Miller KC, et al. Clinical activity of lenalidomide (L) (Revlimid\u2122) in patients (PTS) with relapsed or refractory chronic lymphoblastic leukemia (CLL) [abstract 97]. Hematol J. 2005;90: 39."},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Lin TS, Heerema NA, Swenor J. A phase II study of the TNF inhibitor etanercept and thrice weekly rituximab: evidence of clinical activity in the absence of del(17p13.1) genomic abnormalities [abstract]. Blood. 2004;104: 3469a. Abstract 3469.","DOI":"10.1182\/blood.V104.11.3469.3469"},{"key":"2019111823493236300_REF76","doi-asserted-by":"crossref","unstructured":"Byrd JC, O'Brien S, Flinn I, et al. Safety and efficacy results from a phase I trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia [abstract 2503]. Blood. 2004; 104: 2503a.","DOI":"10.1182\/blood.V104.11.2503.2503"},{"key":"2019111823493236300_REF77","doi-asserted-by":"crossref","unstructured":"Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104: 2600-2602.","DOI":"10.1182\/blood-2003-12-4321"},{"key":"2019111823493236300_REF78","doi-asserted-by":"crossref","unstructured":"Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23: 3433-3438.","DOI":"10.1200\/JCO.2005.04.531"},{"key":"2019111823493236300_REF79","doi-asserted-by":"crossref","unstructured":"Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia. 2002;16: 985-992.","DOI":"10.1038\/sj.leu.2402530"},{"key":"2019111823493236300_REF80","doi-asserted-by":"crossref","unstructured":"Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25: 717-722.","DOI":"10.1038\/sj.bmt.1702237"},{"key":"2019111823493236300_REF81","doi-asserted-by":"crossref","unstructured":"Michallet M, Thiebaut A, Dreger P, et al. Peripheral-blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European-blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol. 2000;108: 595-601.","DOI":"10.1046\/j.1365-2141.2000.01900.x"},{"key":"2019111823493236300_REF82","unstructured":"Horowitz M, Montserrat E, Sobocinski K, et al. Haematopoietic stem cell transplantation for chronic lymphocytic leukaemia [abstract 2245]. Blood. 2000;96: 522."},{"key":"2019111823493236300_REF83","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy. 2002;4: 217-221.","DOI":"10.1080\/146532402320219736"},{"key":"2019111823493236300_REF84","doi-asserted-by":"crossref","unstructured":"Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. 2002;29: 817-823.","DOI":"10.1038\/sj.bmt.1703548"},{"key":"2019111823493236300_REF85","unstructured":"Esteve J, Montserrat E, Dreger P. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants [abstract 2013]. Blood. 2001;98: 482."},{"key":"2019111823493236300_REF86","unstructured":"Michallet M, Michallet A-S, Le QH, et al. Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia: a study from the EBMT and IBMT registries [abstract 1729]. Blood. 2003;102: 474."},{"key":"2019111823493236300_REF87","unstructured":"Esteve J, Bosch F, Moreno C, et al. Prolonged response after allogeneic stem-cell transplantation (alloSCT) for high-risk chronic lymphoblastic leukemia (CLL): long term outcome of a series from a single institution [abstract 101]. Haematologica. 2005;90(suppl 2): 41."},{"key":"2019111823493236300_REF88","doi-asserted-by":"crossref","unstructured":"Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol. 2005;23: 5788-5794.","DOI":"10.1200\/JCO.2005.03.962"},{"key":"2019111823493236300_REF89","doi-asserted-by":"crossref","unstructured":"Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood. Prepublished on August 30, 2005, as DOI 10.1182\/blood-2005-05-1778.","DOI":"10.1182\/blood-2005-05-1778"},{"key":"2019111823493236300_REF90","doi-asserted-by":"crossref","unstructured":"Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003;17: 841-848.","DOI":"10.1038\/sj.leu.2402905"},{"key":"2019111823493236300_REF91","doi-asserted-by":"crossref","unstructured":"Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21: 2747-2753.","DOI":"10.1200\/JCO.2003.12.011"},{"key":"2019111823493236300_REF92","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32: 28-35.","DOI":"10.1016\/j.exphem.2003.09.021"},{"key":"2019111823493236300_REF93","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23: 3819-3829.","DOI":"10.1200\/JCO.2005.04.569"},{"key":"2019111823493236300_REF94","doi-asserted-by":"crossref","unstructured":"Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19: 1029-1033.","DOI":"10.1038\/sj.leu.2403745"},{"key":"2019111823493236300_REF95","doi-asserted-by":"crossref","unstructured":"Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97: 631-637.","DOI":"10.1182\/blood.V97.3.631"},{"key":"2019111823493236300_REF96","doi-asserted-by":"crossref","unstructured":"Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral-blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115: 653-659.","DOI":"10.1046\/j.1365-2141.2001.03153.x"},{"key":"2019111823493236300_REF97","doi-asserted-by":"crossref","unstructured":"Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100: 3121-3127.","DOI":"10.1182\/blood-2002-03-0701"},{"key":"2019111823493236300_","doi-asserted-by":"crossref","unstructured":"Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104: 3865-3871.","DOI":"10.1182\/blood-2004-03-1105"},{"key":"2019111823493236300_REF99","unstructured":"Delgado J, Lovell RA, Ewing J, Milligan DW. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for advanced chronic lymphoblastic leukemia [abstract]. Haematologica. 2005;90(suppl 2): 50."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/4\/1276\/468823\/zh800406001276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/4\/1276\/468823\/zh800406001276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T07:34:32Z","timestamp":1626593672000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/4\/1276\/133688\/How-I-treat-refractory-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,15]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-02-0819","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,15]]}}}